诺瓦瓦克斯医药(NVAX.O)股价上涨15%，公司称COVID-19疫苗已获批准。

Core Viewpoint - Novavax Pharmaceuticals (NVAX.O) shares rose by 15% following the announcement that its COVID-19 vaccine has been approved [1] Company Summary - Novavax has received approval for its COVID-19 vaccine, which has positively impacted its stock price, reflecting investor confidence in the company's future prospects [1] Industry Summary - The approval of COVID-19 vaccines continues to play a significant role in the pharmaceutical industry, influencing stock performance and market dynamics [1]